Curative therapy with an allogeneic hematopoietic cell transplant (HCT) can now be offered to a wider patient population due to improvements in donor selection, transplant conditioning regimens, and supportive care measures. However, risk of transplant-related morbidity and mortality remains, and thus appropriate transplant candidate workup pre-HCT for risk stratification and a management plan after HCT is crucial for success of the procedure. These include understanding and identifying risk of underlying malignant disease relapse, graft-versus-host disease, and infectious complications a patient may be predisposed toward, irrespective of allogeneic donor type. Progress in these domains with new therapeutic paradigms allows for development of a treatment plan prior to HCT to mitigate these potential risks tailored to the patient's case. Herein, we present case studies to focus on factors that influence decision-making in HCT and the approaches and strategies used to optimize post-HCT outcomes based on the individual HCT recipient's clinical scenario to improve on these high-risk scenarios.

1.
National Marrow Donor Program, a contractor for the C.W. Bill Young Cell Transplantation Program operated through the U. S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau. Donor Registry
. Last updated April 13,
2022
. https://bloodstemcell.hrsa.gov/data/donation-and-transplantation-statistics. Accessed
April
1
,
2023
.
2.
Bolon YT
AR
,
Allbee-Johnson
M
,
Estrada-Merly
N
,
Lee
SJ
.
Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides
.
2022
.
3.
Artz
AS
.
From biology to clinical practice: aging and hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2012
;
18
:
S40
-
S45
.
doi:10.1016/j.bbmt.2011.11.003.
4.
Tsirigotis
P
,
Byrne
M
,
Schmid
C
, et al.
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
.
Bone Marrow Transplant
.
2016
;
51
(
11
):
1431
-
1438
.
doi:10.1038/bmt.2016.167.
5.
Jimenez Jimenez
AM
,
De Lima
M
,
Komanduri
KV
, et al.
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
.
Bone Marrow Transplant
.
2021
;
56
(
12
):
3068
-
3077
.
doi:10.1038/s41409-021-01450-3.
6.
DeFilipp
Z
,
Chen
Y-B
.
How I treat with maintenance therapy after allogeneic HCT
.
Blood
.
2023
;
141
(
1
):
39
-
48
.
doi:10.1182/blood.2021012412.
7.
Fröhling
S
,
Schlenk
RF
,
Breitruck
J
, et al.
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
.
Blood
.
2002
;
100
(
13
):
4372
-
4380
.
doi:10.1182/blood-2002-05-1440.
8.
Burchert
A
,
Bug
G
,
Fritz
LV
, et al.
Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)
.
J Clin Oncol
.
2020
;
38
(
26
):
2993
-
3002
.
doi:10.1200/JCO.19.03345.
9.
Xuan
L
,
Wang
Y
,
Huang
F
, et al.
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
.
Lancet Oncol
.
2020
;
21
(
9
):
1201
-
1212
.
doi:10.13039/501100001809.
10.
Maziarz
RT
,
Levis
M
,
Patnaik
MM
, et al.
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
.
Bone Marrow Transpl
.
2021
;
56
(
5
):
1180
-
1189
.
doi:10.13039/100008272.
11.
Levis
M
, et al.
BMT-CTN 1506 (MORPHO): a randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML
.
2023
. https://library.ehaweb.org/eha/2023/eha2023-congress/391322/faculty. presenters.bmt-ctn.1506.28morpho29.a.randomized.trial.of.the.flt3.html?f=menu%3D16%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2489% 2Atrend%3D4016%2Amarker%3D4175. Accessed
June
9
,
2023
.
12.
Fathi
AT
,
Kim
HT
,
Soiffer
RJ
, et al.
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
.
Blood Adv
.
2022
;
6
(
22
):
5857
-
5865
.
doi:10.1182/bloodadvances.2022008632.
13.
Fathi
AT
,
Kim
HT
,
Soiffer
RJ
, et al.
Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia
.
Clin Cancer Res
.
2023
;
29
(
11
):
2034
-
2042
.
doi:10.1158/1078-0432.CCR-23-0182.
14.
Papaemmanuil
E
,
Gerstung
M
,
Bullinger
L
, et al.
Genomic classification and prognosis in acute myeloid leukemia
.
N Engl J Med
.
2016
;
374
(
23
):
2209
-
2221
.
doi:10.1056/NEJMoa1516192.
15.
Goodyear
OC
,
Dennis
M
,
Jilani
NY
, et al.
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
.
Blood
.
2012
;
119
(
14
):
3361
-
3369
.
doi:10.1182/blood-2011-09-377044.
16.
Vij
R
,
Le-Rademacher
J
,
Laumann
K
, et al.
A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (Alliance)
.
Biol Blood Marrow Transplant
.
2019
;
25
(
10
):
1984
-
1992
.
doi:10.1016/j.bbmt.2019.06.007.
17.
Pusic
I
,
Choi
J
,
Fiala
MA
, et al.
Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome
.
Biol Blood Marrow Transplant
.
2015
;
21
(
10
):
1761
-
1769
.
doi:10.1016/j.bbmt.2015.05.026.
18.
de Lima
M
,
Giralt
S
,
Thall
PF
, et al.
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study
.
Cancer
.
2010
;
116
(
23
):
5420
-
5431
.
doi:10.1002/cncr.25500.
19.
Oran
B
,
de Lima
M
,
Garcia-Manero
G
, et al.
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
.
Blood Adv
.
2020
;
4
(
21
):
5580
-
5588
.
doi:10.1182/bloodadvances.2020002544.
20.
Wei
Y
,
Xiong
X
,
Li
X
, et al.
Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome
.
Cancer Sci
.
2021
;
112
(
9
):
3636
-
3644
.
doi:10.13039/501100015406.
21.
Luznik
L
,
O'Donnell
PV
,
Symons
HJ
, et al.
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
.
Biol Blood Marrow Transplant
.
2008
;
14
(
6
):
641
-
650
.
doi:10.1016/j.bbmt.2008.03.005.
22.
Ciurea
SO
,
Zhang
M-J
,
Bacigalupo
A-A
, et al.
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
.
Blood
.
2015
;
126
(
8
):
1033
-
1040
.
doi:10.1182/blood-2015-04-639831.
23.
Fuchs
EJ
,
O'Donnell
PV
,
Eapen
M
, et al.
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial
.
Blood
.
2021
;
137
(
3
):
420
-
428
.
doi:10.1182/blood.2020007535.
24.
Rimando
J
,
McCurdy
SR
,
Luznik
L.
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond
.
Blood
.
2023
;
141
(
1
):
49
-
59
.
doi:10.1182/blood.2021015129.
25.
Bolaños-Meade
J
,
Reshef
R
,
Fraser
R
, et al.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
.
Lancet Haematol
.
2019
;
6
(
3
):
e132
-
e143
.
doi:10.13039/100000060.
26.
Bolaños-Meade
J
,
Hamadani
M
,
Wu
J
, et al
;
BMT CTN 1703 Investigators
.
Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis
.
N Engl J Med
.
2023
;
388
(
25
):
2338
-
2348
.
doi:10.1056/NEJMoa2215943.
27.
Luznik
L
,
Pasquini
MC
,
Logan
B
, et al.
Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies
.
J Clin Oncol
.
2022
;
40
(
4
):
356
-
368
.
doi:10.1200/JCO.21.02293.
28.
Watkins
B
,
Qayed
M
,
McCracken
C
, et al.
Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD
.
J Clin Oncol
.
2021
;
39
(
17
):
1865
-
1877
.
doi:10.1200/JCO.20.01086.
29.
Al-Homsi
AS
,
Cirrone
F
,
Wo
S
, et al.
PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
.
Blood Adv
.
2023
;
7
(
14
):
3604
-
3611
.
doi:10.1182/bloodadvances.2023010545.
30.
Al Malki
MM
,
Tsai
N-C
,
Palmer
J
, et al.
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant
.
Blood Adv
.
2021
;
5
(
12
):
2650
-
2659
.
doi:10.1182/bloodadvances.2021004192.
31.
Shaw
BE
,
Jimenez-Jimenez
AM
,
Burns
LJ
, et al.
National Marrow Donor Program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide
.
J Clin Oncol
.
2021
;
39
(
18
):
1971
-
1982
.
doi:10.1200/jco.20.03502.
32.
Al Malki
MM
,
Devine
SM
,
Shaw
BE
, et al.
Access: a multi-center, phase II trial of HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies
.
Blood
.
2022
;
140
:
7591
-
7593
.
doi:10.1182/blood-2022-162581.
33.
Yeh
J
,
Whited
L
,
Saliba
RM
, et al.
Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
.
Blood Adv
.
2021
;
5
(
24
):
5599
-
5607
.
doi:10.1182/bloodadvances.2021004846.
34.
Duléry
R
,
Mohty
R
,
Labopin
M
, et al.
Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation
.
JACC CardioOncol
.
2021
;
3
(
2
):
250
-
259
.
doi:10.1016/j.jaccao.2021.02.011.
35.
Pérez-Valencia
AI
,
Cascos
E
,
Carbonell-Ordeig
S
, et al.
Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant
.
Blood Adv
.
2023
;
7
(
10
):
2018
-
2031
.
doi:10.1182/bloodadvances.2022008792.
36.
Teira
P
,
Battiwalla
M
,
Ramanathan
M
, et al.
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
.
Blood
.
2016
;
127
(
20
):
2427
-
2438
.
doi:10.1182/blood-2015-11-679639.
37.
Goldsmith
SR
,
Abid
MB
,
Auletta
JJ
, et al.
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
.
Blood
.
2021
;
137
(
23
):
3291
-
3305
.
doi:10.1182/blood.2020009362.
38.
Marty
FM
,
Winston
DJ
,
Chemaly
RF
, et al
;
SUPPRESS Trial Clinical Study Group
.
A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2019
;
25
(
2
):
369
-
381
.
doi:10.1016/j.bbmt.2018.09.038.
39.
Marty
FM
,
Ljungman
P
,
Papanicolaou
GA
, et al
;
Maribavir 1263-300 Clinical Study Group
.
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
.
Lancet Infect Dis
.
2011
;
11
(
4
):
284
-
292
.
doi:10.1016/s1473-3099(11)70024-x.
40.
Marty
FM
,
Ljungman
P
,
Chemaly
RF
, et al.
Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation
.
N Engl J Med
.
2017
;
377
(
25
):
2433
-
2444
.
doi:10.1056/nejmoa1706640.
41.
Singh
A
,
Dandoy
CE
,
Chen
M
, et al.
Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome
.
Transplant Cell Ther
.
2022
;
28
(
1
):
48.e1
-
48.48.e10
.
doi:10.1016/j.jtct.2021.09.015
.
You do not currently have access to this content.